Navigation Links
Results of the PARTNER Trial Cohort A cost effectiveness analysis reported
Date:11/10/2011

SAN FRANCISCO, CA NOVEMBER 10, 2011 The cost effectiveness of transcatheter aortic valve implantation (TAVR) compared to surgical aortic valve replacement (SAVR) depends on whether TAVR is performed via the femoral artery or transapically, through a small incision in the chest, according to a new study.

Recently, transcatheter aortic valve implantation (TAVR) has been shown to result in similar 12-month survival as surgical aortic valve replacement (SAVR) for high-risk patients with severe aortic stenosis. The potential cost-effectiveness of TAVR versus SAVR in the PARTNER trial was examined and the results were presented today at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation.

The PARTNER trial randomized patients with severe, symptomatic aortic stenosis and high surgical risk to either TAVR (N=348) or SAVR (N=351) and followed them for a minimum of 12 months. Health state utilities were estimated using the EuroQOL (EQ-5D) at baseline, one, six, and 12 months. Detailed medical resource utilization data were collected on all study patients, and hospital billing data were collected for both index and follow-up hospitalizations for any cause from consenting U.S. patients.

The objectives of the study were to combine cost data with survival and Quality of Life (QoL) data to estimate the12-month cost-effectiveness of TAVR compared with AVR and to explore potential differences in costs and cost-effectiveness of TAVR vs. AVR for the transfemoral vs. transapical populations.

Among high risk aortic stenosis patients eligible for the transfemoral approach, TAVR, compared with surgical AVR:

  • Provided small but significant gains in 12 month quality-adjusted life expectancy (0.06 0.07 Quality Adjusted Life Years, QALYs)
  • Was associated with higher procedural costs but slightly lower index hospitalization and total 12 month costs

However, not all patients qualify medically for the transfemoral approach. Among patients only eligible for the transapical approach:

  • TAVR provided no increase (and possible decrease) in QALYs
  • TAVR increased procedural, index admission, and 12 month costs (by ~$10,000/patient)

"Results of this trial indicate that for patients with severe aortic stenosis and high surgical risk, transcatheter aortic valve replacement is an economically attractive and possibly dominant strategy compared with surgical aortic valve replacement, provided that patients are suitable for the transfemoral approach," said Matthew R. Reynolds, MD. Dr. Reynolds is Director of the Economics and Quality of Life Research Center at Harvard Clinical Research Institute (HCRI), an Assistant Professor of Medicine at Harvard Medical School and Associate Director of Electrophysiology at the Boston VA Health Care System.

"Current results for transcatheter aortic valve replacement via the transapical approach, compared with surgical aortic valve replacement, are unattractive from a health economic perspective," said Dr. Reynolds.

"Whether the transapical approach can be refined to provide faster recovery and better results from a cost perspective should be the subject of further study."


'/>"/>

Contact: Judy Romero
jromero@crf.org
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. Combination epigenetic therapy clinical trial results
2. Results of the PARIS registry Reported at TCT 2011
3. Results of the TRIGGER-PCI trial reported at TCT 2011
4. Results of rapid gene trial reported at TCT 2011
5. Results of the BRIDGE trial reported at TCT 2011
6. First results of Angiomax (bivalirudin) vs. heparin in transcatheter aortic valve interventions
7. Osteoarthritis results from inflammatory processes, not just wear and tear, Stanford study suggests
8. E-counselling shows dramatic results in lowering blood pressure
9. Less Frequent Mammograms May Lower False-Positive Results
10. Mayo Clinic wins grant to study ethics of sharing genetic test results with relatives
11. TGen/Virginia G. Piper Cancer Center publish results of new drug for pancreatic cancer patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... ... June 20, 2017 , ... Dr. Manju ... OH for leading-edge care, whether or not they have a referral. Dr. Kejriwal ... WaterLase® iPlus™ laser, she targets bacteria and damaged tissue without affecting the surrounding ...
(Date:6/20/2017)... PA (PRWEB) , ... June 20, 2017 , ... ... at Allegheny Health Network’s (AHN) Jefferson Hospital is providing physicians with advanced capabilities ... scanner provides higher-resolution images than traditional MRIs, enabling doctors to get a more ...
(Date:6/20/2017)... ... June 20, 2017 , ... In ... Stevia Sweetener, Michael P. May, Ph.D., recently accepted the distinguished Sun Corridor Export ... selected Wisdom Natural Brands (WNB), and 16 other businesses from Pima, Pinal, and ...
(Date:6/20/2017)... , ... June 20, 2017 , ... ... agency, recently became re-accredited by the Joint Commission, which accredits and ... accreditation and certification is recognized nationwide as a symbol of quality that reflects ...
(Date:6/20/2017)... ... 20, 2017 , ... MEDI+SIGN, a healthcare technology company that ... Stanowski, DHA, FACHE to the MEDI+SIGN Advisory Board. , “We are eager ... provide invaluable direction for the company,” says Andrew Hoffman, President of MEDI+SIGN. ...
Breaking Medicine News(10 mins):
(Date:6/16/2017)... years ago today, the Monterey Pop Festival opened its gates ... Francisco "Summer of Love."  To celebrate the anniversary, Northern Light® ... market research portals that it will begin delivering to customers ... "Summer of Love (For Our Customers)."  ... Northern Light ...
(Date:6/14/2017)... June 14, 2017 The Bio Supply Management ... City of Fremont and the Biomedical Manufacturing ... industry in California by providing ... networking, and fostering workforce development. The primary focus of ... of start-ups, as well as small and mid-sized biomedical ...
(Date:6/13/2017)... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), ... U.S. Food and Drug Administration (FDA) has notified the Company ... its Zhejiang, China manufacturing facility has ... successful clearance of the Warning Letter related to our ... measure of the progress we have made in our ongoing ...
Breaking Medicine Technology: